Evidence map›Paper›PMID 41278823›Full record

ArticlebioRxiv : the preprint server for biology2025

Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy.

Canping Chen, Kyle P Gribbin, Xi Li, Tugba Y Ozmen, Furkan Ozmen, Shamilene Sivagnanam, James Kim, Katie E Blise, Xinxing Yang, Yi Zhang and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Canping ChenDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0003-4021-8592
Kyle P GribbinDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Xi LiDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tugba Y OzmenDivision of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Furkan OzmenDivision of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Shamilene SivagnanamDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
James KimDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Katie E BliseBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
Xinxing YangDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
Yi ZhangDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Roselyn S DaiDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
Dove KeithBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
Mara H ShermanCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Mu-Shui DaiDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
Lisa M CoussensDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Charles D LopezDepartment of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
Rosalie C SearsBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
Gordon B MillsDivision of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Katelyn T ByrneDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-2459-9041
Zheng XiaDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0003-3364-8324

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individualsU01CA294548 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, FERTIG, ELANA · 2024 to 2025
$5.1M
The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic DataU24CA264128 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Rehan Akbani, Han Liang · 2022 to 2026
$3.9M
Systematic Characterization and Targeting of Neomorphic Drivers in CancerU01CA281902 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Benjamin Deneen, Han Liang · 2023 to 2026
$3.5M
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programsU01CA278923 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Gregory A Cote, Alexander Savio Ramos Guimaraes · 2023 to 2026
$3.3M
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.U01CA253472 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORKUT, ANIL, LIANG, HAN · 2021 to 2025
$2.6M
Characterizing phenotype-associated subpopulations from single-cell sequencing dataR01GM147365 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Zheng Xia · 2023 to 2026
$1.2M
NCI NIH HHS P30 CA069533NCI NIH HHS U01 CA253472NCI NIH HHS U01 CA278923NCI NIH HHS U01 CA281902NCI NIH HHS U01 CA294548NCI NIH HHS U24 CA264128NIGMS NIH HHS R01 GM147365
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. While major histocompatibility complex class II (MHC-II) expression is traditionally associated with professional antigen-presenting cells, its role in PDAC malignant cells remains underexplored. Herein, we utilized single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, bulk RNA sequencing, multiplex immunohistochemistry (mIHC) and ex vivo studies in culture with both human and murine models to investigate the prognostic relevance of MHC-II expression in malignant PDAC cells. Elevated MHC-II expression in malignant cells was strongly associated with increased infiltration of CD4

Indexed as

BioinformaticsImmunomodulatory therapiesPancreatic cancerSingle-cell sequencingSpatial transcriptomicsTumor heterogeneity

Identifiers

PMID41278823
PMCPMC12633208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.